Page 2 - C Diff News Today

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

November’s Gastroenterology Month in Review features an FDA approval, the discontinuation of a phase 3 clinical program, and news about Clostridioides difficile testing and risk factors.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.

A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.

Study finds that doxycycline, an antibiotic typically reserved as an alternative to azithromycin, is associated with reducing clostridioides difficile infections in pneumonia patients.

Kari A. Mergenhagen, PharmD, BCPS, BCIDP, discusses the potential of doxycycline in reducing C difficile infections among hospitalized patients with pneumonia. This interview delves into doxycycline's influence on patients with a prior C difficile history, demographic generalizability, exclusion criteria, and concerns regarding antibiotic resistance.

New PUNCH CD3 analyses show patients who were treated with live fecal microbiota therapy improved their gut health at 8 weeks—which correlated with improved quality-of-life scores.

Results showed autologous FMT was safe and well-tolerated but did not affect time to normalized intestinal habits compared to placebo.

Use of mirtazapine, nortriptyline, and trazodone among hospitalized patients was associated with a greater risk of CDI.

Age, fecal calprotectin level, toxin B PCR cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent CDI.